Calixa, Cubist deal

Cubist acquired fellow infectious disease company Calixa for $92.5 million in cash and up to $310 million in milestones. Cubist will gain CXA-101, a cephalosporin antibiotic in Phase II testing for complicated urinary tract infection (cUTI); and CXA-201, a combination of CXA-101 and beta lactamase (LACTB) inhibitor tazobactam, which is expected to begin Phase II testing for complicated intra-abdominal infections and cUTI in 1H10 and nosocomial pneumonia in 2H10. Cubist said the deal leverages its regulatory experience in antibiotics and its specialized sales force. ...